About Celcuity Inc.
https://www.celcuity.comCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
CEO
Brian F. Sullivan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Jefferies
Buy
Craig-Hallum
Buy
Stifel
Buy
Needham
Buy
Leerink Partners
Outperform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:7.92M
Value:$906.2M
PERCEPTIVE ADVISORS LLC
Shares:2.96M
Value:$338.44M
BLACKROCK, INC.
Shares:2.25M
Value:$257.17M
Summary
Showing Top 3 of 187
About Celcuity Inc.
https://www.celcuity.comCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $42.85M ▼ | $-43.8M ▲ | 0% | $-0.92 ▲ | $-26.39M ▲ |
| Q2-2025 | $0 | $44.01M ▲ | $-45.27M ▼ | 0% | $-1.04 ▼ | $-42.02M ▼ |
| Q1-2025 | $0 | $36.13M ▼ | $-37M ▼ | 0% | $-0.86 ▼ | $-33.78M ▼ |
| Q4-2024 | $0 | $36.39M ▲ | $-36.65M ▼ | 0% | $-0.85 ▼ | $-33.34M ▼ |
| Q3-2024 | $0 | $30.06M | $-29.79M | 0% | $-0.7 | $-26.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $454.98M ▲ | $476M ▲ | $359.04M ▲ | $116.96M ▲ |
| Q2-2025 | $168.39M ▼ | $183.59M ▼ | $139.22M ▲ | $44.38M ▼ |
| Q1-2025 | $205.69M ▼ | $218.13M ▼ | $131.46M ▲ | $86.67M ▼ |
| Q4-2024 | $235.1M ▼ | $245.12M ▼ | $129.5M ▲ | $115.62M ▼ |
| Q3-2024 | $264.06M | $273.04M | $123.33M | $149.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-43.8M ▲ | $-44.82M ▼ | $-257.61M ▼ | $330.32M ▲ | $27.9M ▼ | $-44.91M ▼ |
| Q2-2025 | $-45.27M ▼ | $-36.21M ▼ | $65.86M ▲ | $232K ▼ | $29.88M ▲ | $-36.25M ▼ |
| Q1-2025 | $-37M ▼ | $-35.85M ▼ | $24.26M ▼ | $5.55M ▲ | $-6.04M ▼ | $-35.91M ▼ |
| Q4-2024 | $-36.65M ▼ | $-27.77M ▼ | $37.56M ▲ | $123K ▼ | $9.91M ▲ | $-27.82M ▼ |
| Q3-2024 | $-29.79M | $-20.56M | $1.9M | $802.6K | $-17.86M | $-20.61M |
CEO
Brian F. Sullivan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Jefferies
Buy
Craig-Hallum
Buy
Stifel
Buy
Needham
Buy
Leerink Partners
Outperform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:7.92M
Value:$906.2M
PERCEPTIVE ADVISORS LLC
Shares:2.96M
Value:$338.44M
BLACKROCK, INC.
Shares:2.25M
Value:$257.17M
Summary
Showing Top 3 of 187